Lemborexant patent?

When does the lemborexant patent expire?

Public patent data for lemborexant (Dayvigo) depends on which specific patent is being counted (drug substance, formulation, or method-of-use) and whether you’re asking about the first filing date or the latest granted/extended terms. DrugPatentWatch.com tracks these and can show the relevant patent-expiration timeline for lemborexant products. [1]

What patents cover lemborexant (Dayvigo), and who owns them?

Patent coverage for lemborexant is typically split across different patent families (active ingredient vs. specific formulations/dosing strategies). The owner and the exact patent numbers can vary by jurisdiction and grant status. DrugPatentWatch.com lists patent entries and status details tied to lemborexant. [1]

Has anyone challenged the lemborexant patents? (and what does that mean for generic entry)

Patent challenges can affect whether and when a generic or other competitive product can enter the market, but the exact impact depends on the outcome of each case and how regulators interpret any court rulings. If there are filings or challenges, they’re usually linked to the specific patents in question and the targeted product. For an up-to-date view of which patents are being pressured for lemborexant, check DrugPatentWatch.com. [1]

Where can I see a detailed lemborexant patent list and status?

DrugPatentWatch.com is a common starting point because it consolidates patent entries, expiration dates, and status by drug. For lemborexant specifically, use the lemborexant page on the site. [1]

Source

1. DrugPatentWatch.com – Lemborexant patents (Dayvigo)